Bio-Thera Solutions Gestione

Gestione criteri di controllo 1/4

Bio-Thera Solutions Il CEO è Shengfeng Li, nominato in Mar2019, ha un mandato di 5.67 anni. possiede direttamente 12.97% delle azioni della società, per un valore di CN¥ 1.13B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.7 anni e 5.7 anni.

Informazioni chiave

Shengfeng Li

Amministratore delegato

CN¥2.4m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	5.7yrs
Proprietà del CEO	13.0%
Durata media del management	1.7yrs
Durata media del Consiglio di amministrazione	5.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Oct 09

Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Sep 05

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Jun 06

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Apr 18

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Mar 04

AMMINISTRATORE DELEGATO

Shengfeng Li (65 yo)

5.7yrs

Mandato

CN¥2,408,100

Compensazione

Mr. Shengfeng Li is Founder, CEO, GM & Chairman of Bio-Thera Solutions, Ltd. from May 20, 2022. He was Founder, CEO, GM & Director of Bio-Thera Solutions, Ltd.until May 20, 2022. He was Founder, CEO & Dir...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Shengfeng Li	Founder	5.7yrs	CN¥2.41m	12.97% CN¥ 1.1b
Jinchen Yu	President	less than a year	CN¥2.52m	Nessun dato
Cui Hua Liu	Deputy GM	no data	CN¥2.18m	Nessun dato
Xianming Huang	SVP of Discovery Research & Director	no data	CN¥2.18m	Nessun dato
Dan Yu	Executive Director & Secretary to the Board	2.5yrs	CN¥847.90k	0.069% CN¥ 6.1m
Bryan Yu	Senior Vice President of Technology Development	no data	Nessun dato	Nessun dato
Cai Bao	Senior Vice President of Quality	less than a year	Nessun dato	Nessun dato

1.7yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di 688177 non è considerato esperto (durata media 1.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Shengfeng Li	Founder	5.7yrs	CN¥2.41m	12.97% CN¥ 1.1b
Jinchen Yu	President	5.7yrs	CN¥2.52m	Nessun dato
Cui Hua Liu	Deputy GM	2.5yrs	CN¥2.18m	Nessun dato
Xianming Huang	SVP of Discovery Research & Director	5.5yrs	CN¥2.18m	Nessun dato
Dan Yu	Executive Director & Secretary to the Board	5.7yrs	CN¥847.90k	0.069% CN¥ 6.1m
Jun Qiu	Director	5.7yrs	Nessun dato	Nessun dato
Wang Jianping	Independent Director	5.7yrs	Nessun dato	Nessun dato
Xiao Yun Wu	Chairman of the Board of Supervisors	5.7yrs	Nessun dato	Nessun dato
Dehan Huang	Independent Director	2.5yrs	CN¥120.00k	0.046% CN¥ 4.0m
Henry Wei	Independent Director	2.5yrs	CN¥120.00k	Nessun dato

5.7yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 688177 sono considerati esperti (durata media dell'incarico 5.7 anni).

Bio-Thera Solutions Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Bio-Thera Solutions, Ltd., Annual General Meeting, Apr 18, 2024

Recent updates

New minor risk - Profitability

Third quarter 2024 earnings released: CN¥0.31 loss per share (vs CN¥0.31 loss in 3Q 2023)

Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Bio-Thera Solutions, Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.27 loss in 2Q 2023)

European Medicines Agency (EMA) Approves Bio-Thera Solutions' BAT1706 (Avzivi, bevacizumab), A Biosimilar Referencing Avastin

Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, A Proposed Biosimilar of Keytruda (Pembrolizumab)

Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2206, A Proposed Biosimilar to Stelara in the US and EU

Bio-Thera Solutions, Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin

Price target decreased by 22% to CN¥42.10

First quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.34 loss in 1Q 2023)

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Bio-Thera Solutions, Ltd., Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: CN¥0.95 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Full year 2023 earnings released: CN¥0.97 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026

FDA Approves Bio-Thera Solutions' Avzivi (Bevacizumab-Tnjn), A Biosimilar Referencing Avastin

Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara

Third quarter 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.21 loss in 3Q 2022)

Chugai Pharmaceutical Co., Ltd., Roche, Genentech, Biogen MA Inc. and Bio-Thera Solutions, Ltd. Withdraw Lawsuit

FDA Approves Bio-Thera Solutions, Ltd.'s Partner Biogen Receives Notification from the United States Food and Drug Administration

Second quarter 2023 earnings released: CN¥0.27 loss per share (vs CN¥0.14 loss in 2Q 2022)

Bio-Thera Solutions, Ltd. Announces Positive Phase 1 Clinical Data for Bat8006 (Folate-Receptor-A-Adc) and Presents Phase 1 Dose Escalation Study At the Bethune Obstetrics and Gynecology Forum

Chugai Files Patent Infringement Lawsuit Against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in the U.S

First quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.27 loss in 1Q 2022)

China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra(R) (Tocilizumab)

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306

Third quarter 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.28 loss in 3Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala (mepolizumab)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 profit in 2Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for Bat8009, an Antibody Drug Conjugate Targeting B7-H3 (Cd276) for the Treatment of Advanced Solid Tumors

Bio-Thera Solutions, Ltd Announces First Patient Dosed in Phase 1 Study for Bat8006, an Antibody Drug Conjugate Targeting Folate Receptor A for the Treatment of Advanced Solid Tumors

Biogen Inc. and Bio-Thera Solutions, Ltd. Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate At the Annual European Congress of Rheumatology (EULAR 2022)

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors

First quarter 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.26 loss in 1Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study in Australia Evaluating BAT6026, Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, Anti-PD-1 Antibody

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Australia for BAT6021, ADCC-Enhanced Monoclonal Antibody Targeting TIGIT for Treatment of Solid Tumors

Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6005, a Monoclonal Antibody Targeting TIGIT

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥1.08 (vs CN¥0.34 loss in 2Q 2020)

Bio-Thera Solutions Announces First Patient Dosed in Phase III Clinical Trial for BAT2206

Bio-Thera Solutions Initiates Phase Iii Clinical Trial for Bat2506, A Proposed Biosimilar of Simponi® (Golimumab)

Biogen and Bio-Thera Announces Positive Results From Phase 3 Study of BAT1806

First quarter 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.28 loss in 1Q 2020)

New 90-day low: CN¥25.00

Full year 2020 earnings released: CN¥1.27 loss per share (vs CN¥2.96 loss in FY 2019)

New 90-day low: CN¥25.03

Bio-Thera Solutions,Ltd. Announces FDA Accepts Biologics License Application for BAT1706, a Proposed Biosimilar to Avastin®

Bio-Thera Solutions, Ltd. Announces Initiation of Phase I Clinical Trial for BAT1308, a Monoclonal Antibody Targeting PD-1

Bio-Thera Solutions,Ltd. to Report Fiscal Year 2020 Results on Mar 05, 2021

New 90-day low: CN¥29.33

Bio-Thera Solutions Announces Licensing Agreement with Biomm S.A. to Distribute and Market BAT1706 in Brazil

New 90-day low: CN¥34.21

Bio-Thera Solutions,Ltd. Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)

New 90-day low: CN¥38.59

Bio-Thera Solutions,Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥43.33

New 90-day low: CN¥43.73

New 90-day low - CN¥47.10

New 90-day low - CN¥47.90

Bio-Thera Solutions, Ltd. to Report First Half, 2020 Results on Aug 28, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione